WO2018123906A1 - Composition for external use - Google Patents

Composition for external use Download PDF

Info

Publication number
WO2018123906A1
WO2018123906A1 PCT/JP2017/046238 JP2017046238W WO2018123906A1 WO 2018123906 A1 WO2018123906 A1 WO 2018123906A1 JP 2017046238 W JP2017046238 W JP 2017046238W WO 2018123906 A1 WO2018123906 A1 WO 2018123906A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
external use
mass
present
loxoprofen
Prior art date
Application number
PCT/JP2017/046238
Other languages
French (fr)
Japanese (ja)
Inventor
岡本　浩明
Original Assignee
小林製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 小林製薬株式会社 filed Critical 小林製薬株式会社
Priority to CN201780080086.5A priority Critical patent/CN110099683B/en
Publication of WO2018123906A1 publication Critical patent/WO2018123906A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a composition for external use.
  • Loxoprofen and its pharmaceutically acceptable salts which are propionic non-steroidal antipyretic analgesic / anti-inflammatory agents (NSAIDs) (in the present specification, these may be collectively referred to as “loxoprofen”) and others. Like the NSAID, it has antipyretic, analgesic and anti-inflammatory effects based on the inhibitory action of prostaglandin biosynthesis.
  • NSAIDs propionic non-steroidal antipyretic analgesic / anti-inflammatory agents
  • Patent Document 1 Various external preparations in which loxoprofen is blended as an active ingredient for antipyretic, analgesic and / or anti-inflammatory action have been developed (Patent Document 1). Various external preparations in which diclofenac, which is also NSAID, is further combined with a warming component have been proposed (Patent Document 2).
  • Patent Document 1 describes a composition for external use in which diclofenac is combined with capsaicinoid or the like as a warming component.
  • the inventor uses loxoprofen in combination with capsaicinoid or the like as a warming component, and uses alcohol having 1 to 4 carbon atoms as a solvent (in the present specification, these are sometimes collectively referred to as “lower alcohol”). It was found that the composition for external use has a tendency to brown over time.
  • An object of the present invention is to provide a composition for external use in which browning over time is suppressed.
  • the present inventor has intensively studied to solve the above-mentioned problems. As a result, by blending the lower alcohol to be contained in an amount of 55% by mass or more based on the whole composition, browning with time can be suppressed. I found it.
  • the present invention has been completed by further studies based on such findings, and includes the following aspects.
  • composition for external use (I-1) A composition comprising loxoprofen or a pharmaceutically acceptable salt thereof, capsaicinoid, and an alcohol having 1 to 4 carbon atoms, wherein the alcohol is added to the whole composition The composition for external use which contains 55 mass% or more with respect to. (I-2) The composition for external use according to (I-1), wherein the capsaicinoid is nonanoic acid vanillylamide. (I-3) The composition for external use according to (I-1) or (I-2), further comprising an ester derivative of nicotinic acid. (I-4) The composition for external use according to any one of (I-1) to (I-3), which is used for analgesia. (I-5) The composition for external use according to any one of (I-1) to (I-4), which is a liquid agent.
  • composition containing loxoprofen or a pharmaceutically acceptable salt thereof, a capsaicinoid, and an alcohol having 1 to 4 carbon atoms in which browning with time is suppressed.
  • the external composition of the present invention is a composition containing loxoprofen or a pharmaceutically acceptable salt thereof (loxoprofen), capsaicinoid, and an alcohol having 1 to 4 carbon atoms.
  • the alcohol is contained in an amount of 55% by mass or more based on the entire composition.
  • composition for external use of the present invention contains loxoprofen as an active ingredient having at least one action selected from the group consisting of antipyretic, analgesic and anti-inflammatory actions.
  • Loxoprofen (2- [4- (2-oxocyclopentylmethyl) phenyl] propionic acid) is a propionic acid-based nonsteroidal antipyretic analgesic / antiinflammatory agent (NSAID) having antipyretic, analgesic and anti-inflammatory effects.
  • NSAID nonsteroidal antipyretic analgesic / antiinflammatory agent
  • salts thereof in addition to loxoprofen itself, pharmaceutically acceptable salts thereof can also be used.
  • Such salts include solvates of loxoprofen or a pharmaceutically acceptable salt thereof with water or alcohol. These are known compounds, which can be produced by known methods, and commercially available products can also be used.
  • loxoprofen sodium hydrate is preferred as loxoprofen or a pharmaceutically acceptable salt thereof.
  • the content of loxoprofen is not particularly limited as long as it is an effective effective amount.
  • the content is, for example, 0.1 to 10% by mass, preferably 0.5 to 5% by mass, more preferably 0.5 to 3%, in terms of loxoprofen sodium anhydride, based on the total composition for external use of the present invention. It can be made into the mass%.
  • composition for external use of the present invention contains capsaicinoid as an active ingredient for warming action.
  • N-acyl vanillylamide can be used as capsaicinoid.
  • N-acyl vanillylamide is a known compound as a blood circulation promoter.
  • the acyl group in N-acyl vanillyl amide may be either linear or branched. Further, the carbon number of the acyl group in N-acyl vanillyl amide is not particularly limited, and may be, for example, 5 to 15, preferably 6 to 11.
  • N-acyl vanillyl amide examples include nonanoic acid vanillyl amide and capsaicins such as capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin and homodihydrocapsaicin.
  • a refined product may be used as the capsaicinoid, but a mixture containing other components in addition to capsaicinoid may be used.
  • a mixture containing capsaicinoid include peppers such as pepper extract, pepper tincture, and pepper powder.
  • capsaicinoid one kind of capsaicinoid may be used alone, or two or more kinds may be used in combination.
  • capsaicinoids nonanoic acid vanillylamide is preferable from the viewpoint that it is easier to exhibit the effect of suppressing browning with time by combining with ethanol.
  • the content of capsaicinoid in the present invention is not particularly limited as long as it is effective in terms of efficacy.
  • the content can be, for example, 0.002 to 0.2% by mass with respect to the entire external composition of the present invention, and preferably 0.003 to 0.05 from the viewpoint of the effect of suppressing browning over time.
  • the amount can be set to mass%, more preferably 0.01 to 0.015 mass%.
  • the ratio of capsainoside can also be set in consideration of the ratio to loxoprofen contained in the composition for external use.
  • the ratio of capsainoside is usually in the range of 0.002 to 0.2 parts by mass with respect to 1 part by mass of loxoprofens contained in the composition for external use, preferably 0.003 to 0.05 parts by mass, more preferably 0.01 to 0.015 parts by mass.
  • composition for external use of the present invention can further contain an nicotinic acid ester derivative as an active ingredient for warming action.
  • ADVANTAGE OF THE INVENTION According to this invention, even if it contains the ester derivative of nicotinic acid, the composition for external use which has the outstanding property can be obtained, without producing further browning.
  • the composition for external use of the present invention further contains an ester derivative of nicotinic acid, thereby further enhancing the effect of suppressing browning over time.
  • the ester derivative of nicotinic acid is not particularly limited as long as it is pharmaceutically acceptable, and can be used widely. Examples thereof include nicotinic acid benzyl ester, nicotinic acid ⁇ -butoxyethyl ester and nicotinic acid methyl ester. These ester derivatives of nicotinic acid may be used alone or in combination of two or more. Of the ester derivatives of nicotinic acid, nicotinic acid benzyl ester is preferred.
  • the content of the ester derivative of nicotinic acid in the present invention is not particularly limited as long as it is effective in terms of efficacy.
  • the content can be, for example, 0.002 to 0.2% by mass with respect to the entire external composition of the present invention, and preferably 0.003 to 0.05 from the viewpoint of the effect of suppressing browning over time.
  • the amount can be set to mass%, more preferably 0.008 to 0.015 mass%.
  • the ratio of the ester derivative of nicotinic acid can also be set in consideration of the ratio to loxoprofen contained in the composition for external use.
  • the ratio of the ester derivative of nicotinic acid is usually in the range of 0.002 to 0.2 parts by mass with respect to 1 part by mass of loxoprofens contained in the composition for external use, preferably The amount is 0.003 to 0.05 parts by mass, more preferably 0.008 to 0.015 parts by mass.
  • C1-C4 alcohol lower alcohol
  • the lower alcohol is not particularly limited and can be widely used as long as it functions as an effective base for the above active ingredients.
  • the lower alcohol examples include methanol, ethanol, propyl alcohol and isopropyl alcohol, with ethanol being preferred.
  • the external composition of the present invention contains 55% by mass or more of a lower alcohol with respect to the entire composition. Thereby, the composition for external use of the present invention is one in which browning with time is suppressed.
  • the external composition of the present invention preferably contains 90% by mass or less, more preferably 80% by mass or less, of the lower alcohol with respect to the entire composition.
  • composition for external use of the present invention preferably contains 60% by mass or more of a lower alcohol with respect to the entire composition from the viewpoint of the effect of suppressing browning over time.
  • the composition for external use of the present invention contains 55 to 90% by mass of the lower alcohol with respect to the whole composition, thereby suppressing the skin browning over time while suppressing the skin irritation.
  • the lower alcohol is preferably contained in an amount of 60 to 90% by mass, more preferably 60 to 80% by mass, based on the entire composition.
  • a refreshing agent in the composition for external use of the present invention, can be blended in addition to the above components as long as the effects of the present invention are not hindered.
  • Such refreshing agents include l-menthol, d-menthol, dl-menthol, d-camphor, dl-camphor, d-borneol, dl-borneol, menthane, menthol lactate, geraniol, eucalyptus oil, terpene oil, bergamot oil , Fennel oil, peppermint oil (peppermint), rose oil, cool mint and the like. These cooling agents may be used alone or in any combination of two or more.
  • the refreshing agent contained in the composition for external use of the present invention is preferably l-menthol, d-menthol, dl-menthol, d-borneol, dl-borneol, menthane, peppermint oil (peppermint) and cool mint, Menthol is more preferable, and l-menthol is particularly preferable.
  • a medicinal aid in the composition for external use of the present invention, can be blended in addition to the above components as long as the effects of the present invention are not hindered.
  • Such pharmaceutical adjuvants include anti-inflammatory agents and skin protectants such as glycyrrhetinic acid, dipotassium glycyrrhizinate, ammonium glycyrrhizinate, stearyl glycyrrhizinate; diphenylimidazole, diphenhydramine and pharmaceutically acceptable salts thereof, chlorpheny maleate,
  • skin protectants such as glycyrrhetinic acid, dipotassium glycyrrhizinate, ammonium glycyrrhizinate, stearyl glycyrrhizinate; diphenylimidazole, diphenhydramine and pharmaceutically acceptable salts thereof, chlorpheny maleate
  • antihistamines such as lamin
  • blood circulation promoters such as tocopherol acetate
  • herbal medicines such as arnica tincture, agaric extract, sushi extract, horse chestnut extract, funnel extract, bella
  • composition for external use of the present invention in addition to the above-mentioned components, active ingredients that can be used in combination, pH adjusters, preservatives, preservatives, antioxidants, stabilizers, etc., which are used for usual external compositions
  • An agent can be appropriately blended.
  • composition for external use of the present invention is not particularly limited in form, but is preferably a liquid (including lotions, sprays, aerosols, and emulsions).
  • composition for external use of the present invention can be prepared according to a conventional method depending on the form of the preparation.
  • loxoprofen, capsainoside, or, if necessary, an ester derivative of nicotinic acid mixed with a general-purpose base used in external preparations as described below, including lower alcohols, dissolved or dispersed The method of adjusting to pH can be mentioned.
  • the pH is not limited as long as it does not adversely affect the skin, and is usually adjusted to pH 3.5 to 8.5, preferably pH 4 to 8, more preferably 4 to 7.5.
  • composition for external use of the present invention when the composition for external use of the present invention is prepared as a liquid, by mixing loxoprofen, capsainoside, and, if necessary, an ester derivative of nicotinic acid with a base mainly composed of a lower alcohol.
  • a base mainly composed of a lower alcohol.
  • the base at least one selected from glycols, water and an emulsifier can be blended.
  • glycols are not particularly limited, and examples include glycerin, propylene glycol, 1,3-butylene glycol, octanediol, ethylene glycol, polyethylene glycol, D-sorbitol and the like. Glycerin, propylene glycol and 1,3-butylene glycol are preferred.
  • a glycol may be used individually by 1 type and may be used in combination of multiple types.
  • the emulsifier is not particularly limited, and examples thereof include nonionic surfactants such as sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyl stearate, and lauromacrogol.
  • An emulsifier may be used individually by 1 type and may be used in combination of multiple types.
  • the external composition of the present invention is preferably prepared as an external preparation in the form of a coating and can be locally administered externally.
  • the dosage of the composition for external use of the present invention depends on the degree of the symptom to be treated. However, the dosage per day of loxoprofen, which is an active ingredient contained therein, is 100 mg or less. It is desirable to be.
  • composition for external use of the present invention is a topical anti-inflammatory analgesic, such as shoulder pain associated with stiff shoulders, joint pain, low back pain, muscle pain, tendonitis (hand / wrist pain), elbow pain (tennis elbow etc.), bruise pain, It can be suitably used for the purpose of analgesia against pains such as pain, fractures, and neuralgia.
  • analgesic such as shoulder pain associated with stiff shoulders, joint pain, low back pain, muscle pain, tendonitis (hand / wrist pain), elbow pain (tennis elbow etc.), bruise pain
  • the method of the present invention comprises a composition comprising loxoprofen or a pharmaceutically acceptable salt thereof, capsaicinoid and an alcohol having 1 to 4 carbon atoms. In which the content ratio of the alcohol to the entire composition is 55% by mass or more.
  • Each component to be blended in such a composition including loxoprofen and capsaicinoid, is as described for the external composition of the present invention of (I) above.
  • the step of setting the content ratio of the alcohol to the entire composition to 55% by mass or more is not particularly limited, and may be performed by mixing each component as described for the external composition of the present invention of (I) above. it can.
  • the order of mixing is not particularly limited.
  • an embodiment in which the effect can be exhibited to a higher degree is an embodiment in which an ester derivative of nicotinic acid is further added to the composition in addition to loxoprofen and capsaicinoid.
  • the unit represents mass (g) (that is, mass%) per 100 g of the composition.
  • each component was weighed and weighed, and a liquid composition was prepared by stirring and dissolving (Examples 1 to 6, Comparative Examples 1 to 4).
  • FIG. 1 shows photographs of “ ⁇ ” and “ ⁇ ”. The left side is a photograph of “ ⁇ ” (Example 1) and the right side is “ ⁇ ” (Comparative Example 3).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

[Problem] To provide a composition for external use which contains a loxoprofen compound as an active ingredient, the composition being less apt to change to brown with the lapse of time. [Solution] A composition for external use which comprises either loxoprofen or a pharmaceutically acceptable salt thereof, a capsaicinoid, and a C1-4 alcohol, wherein the alcohol is contained in an amount of 55 mass% or larger with respect to the whole composition.

Description

外用組成物Composition for external use
　本発明は外用組成物に関する。 The present invention relates to a composition for external use.
　プロピオン酸系非ステロイド性解熱鎮痛消炎剤（ＮＳＡＩＤ）である、ロキソプロフェン及びその薬学的に許容される塩（本明細書において、これらを総称して「ロキソプロフェン類」ということがある。）は、その他のＮＳＡＩＤと同様、プロスタグランジン生合成の抑制作用に基づく解熱、鎮痛及び消炎作用を有する。 Loxoprofen and its pharmaceutically acceptable salts, which are propionic non-steroidal antipyretic analgesic / anti-inflammatory agents (NSAIDs) (in the present specification, these may be collectively referred to as “loxoprofen”) and others. Like the NSAID, it has antipyretic, analgesic and anti-inflammatory effects based on the inhibitory action of prostaglandin biosynthesis.
　ロキソプロフェン類を、解熱、鎮痛及び／又は消炎作用の有効成分として配合した外用剤が種々開発されている（特許文献１）。また、同じくＮＳＡＩＤであるジクロフェナク類を、さらに温感成分と組み合わせて配合した外用剤も種々提案されている（特許文献２）。 Various external preparations in which loxoprofen is blended as an active ingredient for antipyretic, analgesic and / or anti-inflammatory action have been developed (Patent Document 1). Various external preparations in which diclofenac, which is also NSAID, is further combined with a warming component have been proposed (Patent Document 2).
　例えば、特許文献１には、ジクロフェナク類に、温感成分としてカプサイシノイド等を組み合わせた外用組成物が記載されている。 For example, Patent Document 1 describes a composition for external use in which diclofenac is combined with capsaicinoid or the like as a warming component.
特開２０１５－９８４６９号公報JP2015-98469A 特開２０１１－７４０３２号公報JP 2011-74032 A
　本発明者は、ロキソプロフェン類に、温感成分としてカプサイシノイド等を組み合わせ、溶媒として炭素数１～４のアルコール（本明細書において、これらを総称して「低級アルコール」ということがある。）を用いた外用組成物においては、経時的に褐変していくという傾向があることを見出した。本発明は、かかる経時的な褐変が抑制された外用組成物を提供することを課題とする。 The inventor uses loxoprofen in combination with capsaicinoid or the like as a warming component, and uses alcohol having 1 to 4 carbon atoms as a solvent (in the present specification, these are sometimes collectively referred to as “lower alcohol”). It was found that the composition for external use has a tendency to brown over time. An object of the present invention is to provide a composition for external use in which browning over time is suppressed.
　本発明者は、上記課題を解決すべく、鋭意検討を行ったところ、低級アルコールを組成物全体に対して５５質量％以上含まれるよう配合することにより、経時的な褐変が抑制されることを見出した。本発明はかかる知見に基づいてさらに検討を加えることにより完成したものであり、以下の態様を含む。 The present inventor has intensively studied to solve the above-mentioned problems. As a result, by blending the lower alcohol to be contained in an amount of 55% by mass or more based on the whole composition, browning with time can be suppressed. I found it. The present invention has been completed by further studies based on such findings, and includes the following aspects.
　（Ｉ）外用組成物
（I-1）　ロキソプロフェン又はその薬学的に許容される塩と、カプサイシノイドと、炭素数１～４のアルコールとを含有する組成物であって、該アルコールを、組成物全体に対して５５質量％以上含有する、外用組成物。
（I-2）　前記カプサイシノイドが、ノナン酸バニリルアミドである、（I-1）に記載の外用組成物。
（I-3）　さらに、ニコチン酸のエステル誘導体を含有する、（I-1）又は（I-2）に記載の外用組成物。
（I-4）　鎮痛用途で用いられる、（I-1）～（I-3）のいずれか一項に記載の外用組成物。
（I-5）　液剤である、（I-1）～（I-4）のいずれか一項に記載の外用組成物。 (I) Composition for external use (I-1) A composition comprising loxoprofen or a pharmaceutically acceptable salt thereof, capsaicinoid, and an alcohol having 1 to 4 carbon atoms, wherein the alcohol is added to the whole composition The composition for external use which contains 55 mass% or more with respect to.
(I-2) The composition for external use according to (I-1), wherein the capsaicinoid is nonanoic acid vanillylamide.
(I-3) The composition for external use according to (I-1) or (I-2), further comprising an ester derivative of nicotinic acid.
(I-4) The composition for external use according to any one of (I-1) to (I-3), which is used for analgesia.
(I-5) The composition for external use according to any one of (I-1) to (I-4), which is a liquid agent.
　（II）ロキソプロフェン類及びカプサイシノイドを含有する組成物の経時的褐変の抑制方法
（II-1）　ロキソプロフェン又はその薬学的に許容される塩と、カプサイシノイドと、炭素数１～４のアルコールとを含有する組成物の経時的褐変を抑制する方法であって、該アルコールの組成物全体に対する含有割合を５５質量％以上にする工程を含む方法。
（II-2）　前記カプサイシノイドが、ノナン酸バニリルアミドである、（II-1）に記載の方法。
（II-3）　前記組成物が、さらに、ニコチン酸のエステル誘導体を含有する、（II-1）又は（II-2）に記載の方法。
（II-4）　前記組成物が、液剤である、（II-1）～（II-3）のいずれか一項に記載の方法。 (II) Method for inhibiting temporal browning of a composition containing loxoprofen and capsaicinoid (II-1) containing loxoprofen or a pharmaceutically acceptable salt thereof, capsaicinoid and an alcohol having 1 to 4 carbon atoms A method for suppressing browning of a composition over time, comprising a step of setting the content ratio of the alcohol to the whole composition to 55% by mass or more.
(II-2) The method according to (II-1), wherein the capsaicinoid is nonanoic acid vanillylamide.
(II-3) The method according to (II-1) or (II-2), wherein the composition further contains an ester derivative of nicotinic acid.
(II-4) The method according to any one of (II-1) to (II-3), wherein the composition is a liquid agent.
　本発明によれば、ロキソプロフェン又はその薬学的に許容される塩と、カプサイシノイドと、炭素数１～４のアルコールとを含有する組成物であって、経時的褐変が抑制された組成物を提供できる。 According to the present invention, it is possible to provide a composition containing loxoprofen or a pharmaceutically acceptable salt thereof, a capsaicinoid, and an alcohol having 1 to 4 carbon atoms, in which browning with time is suppressed. .
実施例１と比較例３の褐変観察結果を示す写真である。It is a photograph which shows the browning observation result of Example 1 and Comparative Example 3.
１．外用組成物及びその調製方法
　本発明の外用組成物は、ロキソプロフェン又はその薬学的に許容される塩（ロキソプロフェン類）と、カプサイシノイドと、炭素数１～４のアルコールとを含有する組成物であって、該アルコールを、組成物全体に対して５５質量％以上含有する。 1. External composition and preparation method thereof The external composition of the present invention is a composition containing loxoprofen or a pharmaceutically acceptable salt thereof (loxoprofen), capsaicinoid, and an alcohol having 1 to 4 carbon atoms. The alcohol is contained in an amount of 55% by mass or more based on the entire composition.
１．１．ロキソプロフェン及びその薬学的に許容される塩（ロキソプロフェン類）
　本発明の外用組成物は、ロキソプロフェン類を、解熱、鎮痛及び消炎作用からなる群より選択される少なくとも一種の作用の有効成分として含有する。 1.1. Loxoprofen and pharmaceutically acceptable salts thereof (loxoprofen)
The composition for external use of the present invention contains loxoprofen as an active ingredient having at least one action selected from the group consisting of antipyretic, analgesic and anti-inflammatory actions.
　ロキソプロフェン（２－［４－（２－オキソシクロペンチルメチル）フェニル］プロピオン酸）は、解熱、鎮痛及び消炎作用を有するプロピオン酸系非ステロイド性解熱鎮痛消炎剤（ＮＳＡＩＤ）である。 Loxoprofen (2- [4- (2-oxocyclopentylmethyl) phenyl] propionic acid) is a propionic acid-based nonsteroidal antipyretic analgesic / antiinflammatory agent (NSAID) having antipyretic, analgesic and anti-inflammatory effects.
　本発明ではロキソプロフェンそのものの他、その薬学的に許容される塩も使用することができる。かかる塩には、ロキソプロフェン又はその薬学上許容される塩と、水又はアルコール等との溶媒和物も含まれる。これらは公知の化合物であり、公知の方法により製造できるほか、市販のものを用いることもできる。 In the present invention, in addition to loxoprofen itself, pharmaceutically acceptable salts thereof can also be used. Such salts include solvates of loxoprofen or a pharmaceutically acceptable salt thereof with water or alcohol. These are known compounds, which can be produced by known methods, and commercially available products can also be used.
　本発明において、ロキソプロフェン又はその薬学的に許容される塩としては、ロキソプロフェンナトリウム水和物が好ましい。 In the present invention, loxoprofen sodium hydrate is preferred as loxoprofen or a pharmaceutically acceptable salt thereof.
　ロキソプロフェン類の含有量は、効能上有効量であればよく特に制限されない。含有量は、本発明の外用組成物全体に対して、ロキソプロフェンナトリウム無水物換算で、例えば、０．１～１０質量％、好ましくは０．５～５質量％、さらに好ましくは０．５～３質量％とすることができる。 The content of loxoprofen is not particularly limited as long as it is an effective effective amount. The content is, for example, 0.1 to 10% by mass, preferably 0.5 to 5% by mass, more preferably 0.5 to 3%, in terms of loxoprofen sodium anhydride, based on the total composition for external use of the present invention. It can be made into the mass%.
１．２．カプサイシノイド
　本発明の外用組成物は、カプサイシノイドを、温感作用の有効成分として含有する。 1.2. Capsaicinoid The composition for external use of the present invention contains capsaicinoid as an active ingredient for warming action.
　カプサイシノイドとしては、Ｎ－アシルワニリルアミドを使用できる。Ｎ－アシルワニリルアミドは、血行促進剤として公知の化合物である。 N-acyl vanillylamide can be used as capsaicinoid. N-acyl vanillylamide is a known compound as a blood circulation promoter.
　Ｎ－アシルワニリルアミドにおけるアシル基は、直鎖状又は分岐状のいずれであってもよい。また、Ｎ－アシルワニリルアミドにおけるアシル基の炭素数については、特に制限されず、例えば５～１５、好ましくは６～１１等とすることができる。 The acyl group in N-acyl vanillyl amide may be either linear or branched. Further, the carbon number of the acyl group in N-acyl vanillyl amide is not particularly limited, and may be, for example, 5 to 15, preferably 6 to 11.
　Ｎ－アシルワニリルアミドとして、具体的には、ノナン酸バニリルアミド並びに；カプサイシン、ジヒドロカプサイシン、ノルジヒドロカプサイシン、ホモカプサイシン及びホモジヒドロカプサイシン等のカプサイシン類等が挙げられる。 Specific examples of N-acyl vanillyl amide include nonanoic acid vanillyl amide and capsaicins such as capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin and homodihydrocapsaicin.
　本発明において、カプサイシノイドは、精製品を使用してもよいが、カプサイシノイド以外に他の成分が含まれている混合物を使用してもよい。このようなカプサイシノイドを含む混合物としては、具体的には、トウガラシエキス、トウガラシチンキ及びトウガラシ末等のトウガラシ類が挙げられる。 In the present invention, a refined product may be used as the capsaicinoid, but a mixture containing other components in addition to capsaicinoid may be used. Specific examples of such a mixture containing capsaicinoid include peppers such as pepper extract, pepper tincture, and pepper powder.
　本発明において、カプサイシノイドとしては、１種のカプサイシノイドを単独で使用してもよく、また、２種以上を組み合わせて使用してもよい。カプサイシノイドの中でも、エタノールと組み合わせることで経時的褐変の抑制効果をより発揮させやすいという観点から、ノナン酸バニリルアミドが好ましい。 In the present invention, as a capsaicinoid, one kind of capsaicinoid may be used alone, or two or more kinds may be used in combination. Among capsaicinoids, nonanoic acid vanillylamide is preferable from the viewpoint that it is easier to exhibit the effect of suppressing browning with time by combining with ethanol.
　本発明におけるカプサイシノイドの含有量は、効能上有効量であればよく特に制限されない。含有量は、本発明の外用組成物全体に対して、例えば０．００２～０．２質量％とすることができ、経時的褐変の抑制効果の観点で、好ましくは０．００３～０．０５質量％、さらに好ましくは０．０１～０．０１５質量％とすることができる。 The content of capsaicinoid in the present invention is not particularly limited as long as it is effective in terms of efficacy. The content can be, for example, 0.002 to 0.2% by mass with respect to the entire external composition of the present invention, and preferably 0.003 to 0.05 from the viewpoint of the effect of suppressing browning over time. The amount can be set to mass%, more preferably 0.01 to 0.015 mass%.
　なお、カプサイノシドの割合は、外用組成物中に含まれるロキソプロフェン類に対する割合を考慮して設定することもできる。具体的には、外用組成物中に含まれるロキソプロフェン類１質量部に対して、カプサイノシドの割合が通常０．００２～０．２質量部の範囲になるように設定され、好ましくは０．００３～０．０５質量部、さらに好ましくは０．０１～０．０１５質量部である。 In addition, the ratio of capsainoside can also be set in consideration of the ratio to loxoprofen contained in the composition for external use. Specifically, the ratio of capsainoside is usually in the range of 0.002 to 0.2 parts by mass with respect to 1 part by mass of loxoprofens contained in the composition for external use, preferably 0.003 to 0.05 parts by mass, more preferably 0.01 to 0.015 parts by mass.
１．３．ニコチン酸のエステル誘導体
　本発明の外用組成物は、さらに、温感作用の有効成分として、ニコチン酸のエステル誘導体を含有することができる。本発明によれば、ニコチン酸のエステル誘導体を含有させても、さらなる褐変を生じさせることなく、優れた性状を有する外用組成物を得ることができる。 1.3. Nicotinic Acid Ester Derivative The composition for external use of the present invention can further contain an nicotinic acid ester derivative as an active ingredient for warming action. ADVANTAGE OF THE INVENTION According to this invention, even if it contains the ester derivative of nicotinic acid, the composition for external use which has the outstanding property can be obtained, without producing further browning.
　好ましい態様においては、本発明の外用組成物は、さらにニコチン酸のエステル誘導体を含有することにより、経時的褐変の抑制効果がより高められている。 In a preferred embodiment, the composition for external use of the present invention further contains an ester derivative of nicotinic acid, thereby further enhancing the effect of suppressing browning over time.
　ニコチン酸のエステル誘導体としては、薬学的に許容されることを限度として特に制限されず、幅広く使用できる。例えば、ニコチン酸ベンジルエステル、ニコチン酸β－ブトキシエチルエステル及びニコチン酸メチルエステル等が挙げられる。これらのニコチン酸のエステル誘導体は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。ニコチン酸のエステル誘導体の中でも、ニコチン酸ベンジルエステルが好ましい。 The ester derivative of nicotinic acid is not particularly limited as long as it is pharmaceutically acceptable, and can be used widely. Examples thereof include nicotinic acid benzyl ester, nicotinic acid β-butoxyethyl ester and nicotinic acid methyl ester. These ester derivatives of nicotinic acid may be used alone or in combination of two or more. Of the ester derivatives of nicotinic acid, nicotinic acid benzyl ester is preferred.
　本発明におけるニコチン酸のエステル誘導体の含有量は、効能上有効量であればよく特に制限されない。含有量は、本発明の外用組成物全体に対して、例えば０．００２～０．２質量％とすることができ、経時的褐変の抑制効果の観点で、好ましくは０．００３～０．０５質量％、さらに好ましくは０．００８～０．０１５質量％とすることができる。 The content of the ester derivative of nicotinic acid in the present invention is not particularly limited as long as it is effective in terms of efficacy. The content can be, for example, 0.002 to 0.2% by mass with respect to the entire external composition of the present invention, and preferably 0.003 to 0.05 from the viewpoint of the effect of suppressing browning over time. The amount can be set to mass%, more preferably 0.008 to 0.015 mass%.
　なお、ニコチン酸のエステル誘導体の割合は、外用組成物中に含まれるロキソプロフェン類に対する割合を考慮して設定することもできる。具体的には、外用組成物中に含まれるロキソプロフェン類１質量部に対して、ニコチン酸のエステル誘導体の割合が通常０．００２～０．２質量部の範囲になるように設定され、好ましくは０．００３～０．０５質量部、さらに好ましくは０．００８～０．０１５質量部である。 In addition, the ratio of the ester derivative of nicotinic acid can also be set in consideration of the ratio to loxoprofen contained in the composition for external use. Specifically, the ratio of the ester derivative of nicotinic acid is usually in the range of 0.002 to 0.2 parts by mass with respect to 1 part by mass of loxoprofens contained in the composition for external use, preferably The amount is 0.003 to 0.05 parts by mass, more preferably 0.008 to 0.015 parts by mass.
１．４．炭素数１～４のアルコール（低級アルコール）
　低級アルコールは、特に限定されず、上記の有効成分に対して有効な基剤として機能するものであれば幅広く使用できる。 1.4. C1-C4 alcohol (lower alcohol)
The lower alcohol is not particularly limited and can be widely used as long as it functions as an effective base for the above active ingredients.
　低級アルコールとしては、具体的には、例えば、メタノール、エタノール、プロピルアルコール及びイソプロピルアルコール等を挙げることができ、エタノールが好ましい。 Specific examples of the lower alcohol include methanol, ethanol, propyl alcohol and isopropyl alcohol, with ethanol being preferred.
　本発明の外用組成物は、低級アルコールを、組成物全体に対して５５質量％以上含有する。このことにより、本発明の外用組成物は、経時的褐変が抑制されたものとなる。 The external composition of the present invention contains 55% by mass or more of a lower alcohol with respect to the entire composition. Thereby, the composition for external use of the present invention is one in which browning with time is suppressed.
　本発明の外用組成物は、皮膚刺激を抑制するという観点で、低級アルコールを、組成物全体に対して、９０質量％以下含有することが好ましく、８０質量％以下含有することがより好ましい。 From the viewpoint of suppressing skin irritation, the external composition of the present invention preferably contains 90% by mass or less, more preferably 80% by mass or less, of the lower alcohol with respect to the entire composition.
　本発明の外用組成物は、経時的褐変の抑制効果の観点で、低級アルコールを、組成物全体に対して、６０質量％以上含有することが好ましい。 The composition for external use of the present invention preferably contains 60% by mass or more of a lower alcohol with respect to the entire composition from the viewpoint of the effect of suppressing browning over time.
　したがって、本発明の外用組成物は、低級アルコールを、組成物全体に対して、５５～９０質量％含有していることにより、皮膚刺激を抑えながら、外用組成物の経時的褐変も抑制することができ、この観点で、低級アルコールを組成物全体に対して、６０～９０質量％含有していることが好ましく、６０～８０質量％含有していることがより好ましい。 Therefore, the composition for external use of the present invention contains 55 to 90% by mass of the lower alcohol with respect to the whole composition, thereby suppressing the skin browning over time while suppressing the skin irritation. From this point of view, the lower alcohol is preferably contained in an amount of 60 to 90% by mass, more preferably 60 to 80% by mass, based on the entire composition.
１．５．その他の成分
　本発明の外用組成物には、本発明の効果を妨げない限り、上記成分の他に、清涼化剤を配合することもできる。 1.5. Other Components In the composition for external use of the present invention, a refreshing agent can be blended in addition to the above components as long as the effects of the present invention are not hindered.
　かかる清涼化剤としては、ｌ－メントール、ｄ－メントール、ｄｌ－メントール、ｄ－カンフル、ｄｌ－カンフル、ｄ－ボルネオール、ｄｌ－ボルネオール、メンタン、乳酸メンチル、ゲラニオール、ユーカリ油、テルペン油、ベルガモット油、ウィキョウ油、ハッカ油（ペパーミント）、ローズ油及びクールミント等が挙げられる。これらの清涼化剤は、１種単独で使用しても、また２種以上を任意に組み合わせて使用してもよい。 Such refreshing agents include l-menthol, d-menthol, dl-menthol, d-camphor, dl-camphor, d-borneol, dl-borneol, menthane, menthol lactate, geraniol, eucalyptus oil, terpene oil, bergamot oil , Fennel oil, peppermint oil (peppermint), rose oil, cool mint and the like. These cooling agents may be used alone or in any combination of two or more.
　本発明の外用組成物に含まれる清涼化剤は、好ましくは、ｌ－メントール、ｄ－メントール、ｄｌ－メントール、ｄ－ボルネオール、ｄｌ－ボルネオール、メンタン、ハッカ油（ペパーミント）及びクールミントであり、より好ましくはメントールであり、特に好ましくはｌ－メントールである。 The refreshing agent contained in the composition for external use of the present invention is preferably l-menthol, d-menthol, dl-menthol, d-borneol, dl-borneol, menthane, peppermint oil (peppermint) and cool mint, Menthol is more preferable, and l-menthol is particularly preferable.
　本発明の外用組成物には、本発明の効果を妨げない限り、上記成分の他に、薬効補助剤を配合することもできる。 In the composition for external use of the present invention, a medicinal aid can be blended in addition to the above components as long as the effects of the present invention are not hindered.
　かかる薬効補助剤としては、グリチルレチン酸、グリチルリチン酸二カリウム、グリチルリチン酸アンモニウム、グリチルリチン酸ステアリル等の抗炎症剤や皮膚保護剤；ジフェニルイミダゾール、ジフェンヒドラミン及びその薬学的に許容される塩、マレイン酸クロルフェニラミン等の抗ヒスタミン剤；酢酸トコフェロール等の血行促進剤；アルニカチンキ、オウバクエキス、サンシシエキス、セイヨウトチノキエキス、ロートエキス、ベラドンナエキス、トウキエキス、シコンエキス、サンショウエキス等の生薬等が挙げられる。 Such pharmaceutical adjuvants include anti-inflammatory agents and skin protectants such as glycyrrhetinic acid, dipotassium glycyrrhizinate, ammonium glycyrrhizinate, stearyl glycyrrhizinate; diphenylimidazole, diphenhydramine and pharmaceutically acceptable salts thereof, chlorpheny maleate, Examples include antihistamines such as lamin; blood circulation promoters such as tocopherol acetate; herbal medicines such as arnica tincture, agaric extract, sushi extract, horse chestnut extract, funnel extract, belladonna extract, toki extract, chicory extract, and salamander extract.
　本発明の外用組成物には、上記の成分の他、併用可能な活性成分、ｐＨ調節剤、防腐剤、保存剤、酸化防止剤、安定化剤等の通常の外用組成物に使用される添加剤を適宜配合することができる。 In the composition for external use of the present invention, in addition to the above-mentioned components, active ingredients that can be used in combination, pH adjusters, preservatives, preservatives, antioxidants, stabilizers, etc., which are used for usual external compositions An agent can be appropriately blended.
１．６．形態および製造方法
　本発明の外用組成物は、その形態を特に制限するものではないが、好ましくは液剤（ローション剤、スプレー剤、エアゾール剤、及び乳液剤を含む）である。 1.6. Form and Production Method The composition for external use of the present invention is not particularly limited in form, but is preferably a liquid (including lotions, sprays, aerosols, and emulsions).
　本発明の外用組成物は、かかる製剤形態に応じて、定法に従って調製することができる。例えば、ロキソプロフェン類、カプサイノシド、または必要に応じてニコチン酸のエステル誘導体を、低級アルコールを含む、下記に説明するような外用製剤に用いられる汎用の基剤と混合して溶解又は分散させ、所望のｐＨに調整する方法を挙げることができる。なお、ｐＨとしては皮膚に悪影響のない範囲であれば制限されず、通常ｐＨ３．５～８．５、好ましくはｐＨ４～８、より好ましくは４～７．５になるように調整される。 The composition for external use of the present invention can be prepared according to a conventional method depending on the form of the preparation. For example, loxoprofen, capsainoside, or, if necessary, an ester derivative of nicotinic acid mixed with a general-purpose base used in external preparations as described below, including lower alcohols, dissolved or dispersed, The method of adjusting to pH can be mentioned. The pH is not limited as long as it does not adversely affect the skin, and is usually adjusted to pH 3.5 to 8.5, preferably pH 4 to 8, more preferably 4 to 7.5.
　例えば、本発明の外用組成物を液剤として調製する場合は、ロキソプロフェン類と、カプサイノシドと、さらに必要に応じてニコチン酸のエステル誘導体とを、低級アルコールを主成分とする基剤と混合することにより調製できる。基剤には、グリコール類、水及び乳化剤から選択される少なくとも一種を配合することができる。 For example, when the composition for external use of the present invention is prepared as a liquid, by mixing loxoprofen, capsainoside, and, if necessary, an ester derivative of nicotinic acid with a base mainly composed of a lower alcohol. Can be prepared. In the base, at least one selected from glycols, water and an emulsifier can be blended.
　グリコール類としては、特に限定されず、例えば、グリセリン、プロピレングリコール、１，３－ブチレングリコール、オクタンジオール、エチレングリコール、ポリエチレングリコール、Ｄ‐ソルビトール等が挙げられる。グリセリン、プロピレングリコール及び１，３－ブチレングリコールが好ましい。グリコール類は、一種を単独で使用してもよいし、複数種を組み合わせて使用してもよい。 The glycols are not particularly limited, and examples include glycerin, propylene glycol, 1,3-butylene glycol, octanediol, ethylene glycol, polyethylene glycol, D-sorbitol and the like. Glycerin, propylene glycol and 1,3-butylene glycol are preferred. A glycol may be used individually by 1 type and may be used in combination of multiple types.
　乳化剤としては、特に限定されず、例えば、ソルビタン脂肪酸エステル、グリセリン脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エステル、ステアリン酸ポリオキシル、ラウロマクロゴール等の非イオン性界面活性剤等が挙げられる。乳化剤は、一種を単独で使用してもよいし、複数種を組み合わせて使用してもよい。 The emulsifier is not particularly limited, and examples thereof include nonionic surfactants such as sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyl stearate, and lauromacrogol. An emulsifier may be used individually by 1 type and may be used in combination of multiple types.
　本発明の外用組成物は、好ましくは塗布形態の外用剤として調製され、局所的に外用投与することができる。本発明の外用組成物の投与量は、治療すべき症状の程度により左右されるが、中に含まれている有効成分であるロキソプロフェン類の１日あたりの塗布投与量が１００ｍｇ以下となる量であることが望ましい。 The external composition of the present invention is preferably prepared as an external preparation in the form of a coating and can be locally administered externally. The dosage of the composition for external use of the present invention depends on the degree of the symptom to be treated. However, the dosage per day of loxoprofen, which is an active ingredient contained therein, is 100 mg or less. It is desirable to be.
　本発明の外用組成物は、外用消炎鎮痛剤として、肩こりに伴う肩の痛み、関節痛、腰痛、筋肉痛、腱鞘炎（手・手首の痛み）、肘の痛み（テニス肘等）、打撲痛、ねんざ痛、骨折痛、神経痛等の痛みに対して、鎮痛を目的とする好適に使用することができる。 The composition for external use of the present invention is a topical anti-inflammatory analgesic, such as shoulder pain associated with stiff shoulders, joint pain, low back pain, muscle pain, tendonitis (hand / wrist pain), elbow pain (tennis elbow etc.), bruise pain, It can be suitably used for the purpose of analgesia against pains such as pain, fractures, and neuralgia.
　２．ロキソプロフェン類及びカプサイシノイドを含有する組成物の経時的褐変の抑制方法
　本発明の方法は、ロキソプロフェン又はその薬学的に許容される塩と、カプサイシノイドと、炭素数１～４のアルコールとを含有する組成物の経時的褐変を抑制する方法であって、該アルコールの組成物全体に対する含有割合を５５質量％以上にする工程を含む方法である。 2. Method for inhibiting browning of composition containing loxoprofen and capsaicinoid over time The method of the present invention comprises a composition comprising loxoprofen or a pharmaceutically acceptable salt thereof, capsaicinoid and an alcohol having 1 to 4 carbon atoms. In which the content ratio of the alcohol to the entire composition is 55% by mass or more.
　ロキソプロフェン及びカプサイシノイドをはじめ、かかる組成物に配合される各成分については、前記（Ｉ）の本発明の外用組成物についての説明の通りである。 Each component to be blended in such a composition, including loxoprofen and capsaicinoid, is as described for the external composition of the present invention of (I) above.
　アルコールの組成物全体に対する含有割合を５５質量％以上にする工程は、特に限定されず、前記（Ｉ）の本発明の外用組成物についての説明の通り、各成分を混合することによって行うことができる。混合の順番は特に限定されない。 The step of setting the content ratio of the alcohol to the entire composition to 55% by mass or more is not particularly limited, and may be performed by mixing each component as described for the external composition of the present invention of (I) above. it can. The order of mixing is not particularly limited.
　また本発明の方法において、その効果をより高く発揮できる態様は、組成物に、ロキソプロフェン及びカプサイシノイドに加えて、さらにニコチン酸のエステル誘導体を配合する態様である。 Further, in the method of the present invention, an embodiment in which the effect can be exhibited to a higher degree is an embodiment in which an ester derivative of nicotinic acid is further added to the composition in addition to loxoprofen and capsaicinoid.
　以下、実施例を挙げて本発明を説明するが、本発明はこれらの実施例等に限定されるものではない。なお、表中において単位は組成物１００ｇ当たりの質量（ｇ）（すなわち質量％）を表わす。 Hereinafter, the present invention will be described with reference to examples, but the present invention is not limited to these examples. In the table, the unit represents mass (g) (that is, mass%) per 100 g of the composition.
　表１に記載する通り、各成分を各分量、量り取り、攪拌して溶解させることにより液状組成物を調製した（実施例１～６、比較例１～４）。 As described in Table 1, each component was weighed and weighed, and a liquid composition was prepared by stirring and dissolving (Examples 1 to 6, Comparative Examples 1 to 4).
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
　得られた各組成物を、スクリュー管（マルエム製、Ｎｏ．５、直径２７ｍｍ、高さ５５ｍｍ）に入れ、６０℃で１ヶ月間保管し、性状を観察した。目視にて透明なものを「◎」、褐変傾向の最も強いものを「×」とし、「×～◎」の４段階（悪い順に「×」、「△」、「○」、「◎」）で評価した。結果を表１に示す。図１に「◎」と「×」それぞれの写真を示す。向かって左側が「◎」（実施例１）、右側が「×」（比較例３）の写真である。 Each composition obtained was put in a screw tube (manufactured by Maruemu, No. 5, diameter 27 mm, height 55 mm), stored at 60 ° C. for 1 month, and the properties were observed. Visually transparent material is “◎”, and the one with the strongest browning tendency is “×”, and “X to ◎” is 4 stages (“X”, “△”, “○”, “◎” in order of worse) It was evaluated with. The results are shown in Table 1. FIG. 1 shows photographs of “◎” and “×”. The left side is a photograph of “◎” (Example 1) and the right side is “×” (Comparative Example 3).
　表１に示す通り、エタノール２０質量％にロキソプロフェンナトリウム水和物、ノナン酸バニリルアミドのいずれか、またはその両方を配合した組成物においては、経時的に褐変傾向が見られた（比較例１～４）。 As shown in Table 1, in the composition in which 20% by mass of ethanol was mixed with either loxoprofen sodium hydrate, nonanoic acid vanillylamide or both, a tendency to brown over time was observed (Comparative Examples 1 to 4). ).
　一方、エタノールの量を５５質量％以上にした組成物においては、同様に保管しても褐変傾向が見られず透明性の高い性状のままであった（実施例１～６）。 On the other hand, in the composition in which the amount of ethanol was 55% by mass or more, even when stored in the same manner, no browning tendency was observed and the properties remained highly transparent (Examples 1 to 6).
　エタノール含有量が２０質量％である比較例３を基準とし、そこにさらにニコチン酸ベンジルエステルを加えたとしても依然として褐変が観察された（比較例４）。これに対して、比較例３を基準として、そのエタノール含量を５５質量％以上に変化させただけで、褐変を抑制することができた（実施例４～６）。これらのことから、褐変抑制効果は、エタノール含量を５５質量%以上にすることにより得られるものであることが判る。 Based on Comparative Example 3 having an ethanol content of 20% by mass, browning was still observed even if nicotinic acid benzyl ester was further added thereto (Comparative Example 4). On the other hand, browning could be suppressed only by changing the ethanol content to 55% by mass or more on the basis of Comparative Example 3 (Examples 4 to 6). From these things, it turns out that the browning inhibitory effect is obtained by making ethanol content 55 mass% or more.
　ニコチン酸ベンジルエステル存在下における褐変抑制効果（実施例４～６）は、ニコチン酸ベンジルエステル非存在下における褐変抑制効果（実施例１、２）と比べると、より顕著な傾向にあった。このように、エタノール含有量を５５％以上とすることによる褐変抑制効果は、ニコチン酸ベンジルエステル存在下において顕著に向上することが判明した。 The browning suppression effect in the presence of nicotinic acid benzyl ester (Examples 4 to 6) was more prominent than the browning suppression effect in the absence of nicotinic acid benzyl ester (Examples 1 and 2). Thus, it turned out that the browning inhibitory effect by making ethanol content 55% or more improves notably in presence of nicotinic acid benzyl ester.

Claims (5)

  1. 　ロキソプロフェン又はその薬学的に許容される塩と、カプサイシノイドと、炭素数１～４のアルコールとを含有する組成物であって、該アルコールを、組成物全体に対して５５質量％以上含有する、外用組成物。 A composition containing loxoprofen or a pharmaceutically acceptable salt thereof, a capsaicinoid, and an alcohol having 1 to 4 carbon atoms, the alcohol containing 55% by mass or more based on the total composition Composition.
  2. 　前記カプサイシノイドが、ノナン酸バニリルアミドである、請求項１に記載の外用組成物。 The composition for external use according to claim 1, wherein the capsaicinoid is nonanoic acid vanillylamide.
  3. 　さらに、ニコチン酸のエステル誘導体を含有する、請求項１又は２に記載の外用組成物。 The composition for external use according to claim 1 or 2, further comprising an ester derivative of nicotinic acid.
  4. 　鎮痛用途で用いられる、請求項１～３のいずれか一項に記載の外用組成物。 The composition for external use according to any one of claims 1 to 3, which is used for analgesic use.
  5. 　液剤である、請求項１～４のいずれか一項に記載の外用組成物。 The composition for external use according to any one of claims 1 to 4, which is a liquid agent.
PCT/JP2017/046238 2016-12-27 2017-12-22 Composition for external use WO2018123906A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201780080086.5A CN110099683B (en) 2016-12-27 2017-12-22 External composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016254186A JP6847656B2 (en) 2016-12-27 2016-12-27 Topical composition
JP2016-254186 2016-12-27

Publications (1)

Publication Number Publication Date
WO2018123906A1 true WO2018123906A1 (en) 2018-07-05

Family

ID=62707413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/046238 WO2018123906A1 (en) 2016-12-27 2017-12-22 Composition for external use

Country Status (4)

Country Link
JP (1) JP6847656B2 (en)
CN (1) CN110099683B (en)
TW (1) TWI788316B (en)
WO (1) WO2018123906A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020059666A (en) * 2018-10-09 2020-04-16 小林製薬株式会社 External pharmaceutical composition

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020045315A (en) * 2018-09-20 2020-03-26 興和株式会社 Pharmaceutical preparation containing loxoprofen

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014002599A1 (en) * 2012-06-25 2014-01-03 興和株式会社 Crude-drug-containing pharmaceutical composition
JP2014172857A (en) * 2013-03-08 2014-09-22 Lion Corp External composition
JP2015027971A (en) * 2013-07-31 2015-02-12 興和株式会社 Loxoprofen-containing external application agent
JP2015193540A (en) * 2013-03-29 2015-11-05 興和株式会社 Loxoprofen-containing solid formulation for external use
WO2017111167A1 (en) * 2015-12-25 2017-06-29 興和株式会社 Pharmaceutical preparation containing loxoprofen

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014002599A1 (en) * 2012-06-25 2014-01-03 興和株式会社 Crude-drug-containing pharmaceutical composition
JP2014172857A (en) * 2013-03-08 2014-09-22 Lion Corp External composition
JP2015193540A (en) * 2013-03-29 2015-11-05 興和株式会社 Loxoprofen-containing solid formulation for external use
JP2015027971A (en) * 2013-07-31 2015-02-12 興和株式会社 Loxoprofen-containing external application agent
WO2017111167A1 (en) * 2015-12-25 2017-06-29 興和株式会社 Pharmaceutical preparation containing loxoprofen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020059666A (en) * 2018-10-09 2020-04-16 小林製薬株式会社 External pharmaceutical composition
JP7226957B2 (en) 2018-10-09 2023-02-21 小林製薬株式会社 External pharmaceutical composition

Also Published As

Publication number Publication date
JP6847656B2 (en) 2021-03-24
TWI788316B (en) 2023-01-01
JP2018104368A (en) 2018-07-05
CN110099683B (en) 2023-01-13
CN110099683A (en) 2019-08-06
TW201827046A (en) 2018-08-01

Similar Documents

Publication Publication Date Title
JP5590846B2 (en) Pharmaceutical composition for external use
WO2018123906A1 (en) Composition for external use
JP6900189B2 (en) Topical composition
JP7412871B2 (en) External composition
JP7086597B2 (en) External composition
JP7234268B2 (en) external composition
JP7412870B2 (en) External composition
JP7086596B2 (en) External composition
JP7206042B2 (en) external composition
JP7206043B2 (en) external composition
JP7098320B2 (en) External composition
JP7186025B2 (en) External pharmaceutical composition
WO2019131654A1 (en) Topical formulation
JP7455509B2 (en) External preparations
JP5832602B2 (en) Pharmaceutical composition for external use
JP7229678B2 (en) External pharmaceutical composition
JP7156825B2 (en) External pharmaceutical composition
JP5565995B2 (en) Antipruritic
WO2022270200A1 (en) Aqueous topical composition
WO2015151991A1 (en) Pharmaceutical composition for external use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17888268

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17888268

Country of ref document: EP

Kind code of ref document: A1